In a submitting with the U.S. Securities and Change Fee, vaccine maker Pfizer wrote that gross sales of its COVID-19 vaccine would drop by 70% in 2023.
The vaccine firm pointed to “decrease contracted provides and demand in worldwide markets and decrease US authorities contracted provides because of the transition to new vaccine variants in most markets and the transition to the normal US industrial market beginning in September 2023” as causes for the decline, in accordance with The Epoch Occasions.
Pfizer's vaccine income was $11.2 billion final 12 months. In 2022, the corporate's vaccine income was $37 billion.
Pfizer's whole income fell 42% to $58.5 billion from $100.33 billion.
The lack of income comes because the CDC beneficial that older adults get the most recent booster pictures.
“At the moment's advice permits older adults to get an additional dose of the COVID-19 vaccine for this season to offer extra safety,” stated CDC Director Mandy. “Most COVID-19 deaths and hospitalizations final 12 months have been amongst folks age 65 and older. An extra dose of vaccine might present extra safety which will wane over time in these at highest danger.”
In the meantime, the US authorities's private damage compensation program (CICP) has been delayed by 10 years, in accordance with testimony to the choose subcommittee on the coronavirus pandemic.
Of the two,214 claims reviewed as at 1 January 2024, 40 have been discovered to be eligible for compensation. Of those, solely 11 acquired compensation.
